Moreover, current animal studies support the feasibility of targeted IFN-γ therapy in SLE; however, no obvious effect of targeted IFN therapy has been found in human clinical trials, although some of the inflammatory indicators showed significant changes compared with those in the placebo group. Here, IFNA1 is linked to systemic lupus erythematosus.